Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.

Vatandoust S, Joshi R, Pittman KB, Esterman A, Broadbridge V, Adams J, Singhal N, Yeend S, Price TJ.

Support Care Cancer. 2014 Feb;22(2):513-8.

PMID:
24122404
2.

Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.

Padman S, Lee J, Kumar R, Slee M, Hakendorf P, Richards A, Koczwara B, Kichenadasse G, Sukumaran S, Roy A, Vatandoust S, Karapetis CS.

Support Care Cancer. 2015 Mar;23(3):861-9. doi: 10.1007/s00520-014-2423-9. Epub 2014 Sep 16.

PMID:
25223350
3.

Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.

Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y.

Support Care Cancer. 2013 Dec;21(12):3307-13. doi: 10.1007/s00520-013-1905-5. Epub 2013 Aug 1.

4.

Impact of oxaliplatin-induced neuropathy: a patient perspective.

Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D.

Support Care Cancer. 2012 Nov;20(11):2959-67. doi: 10.1007/s00520-012-1428-5. Epub 2012 Mar 17.

PMID:
22426503
5.

Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.

Tsuruta A, Yamashita K, Tanioka H, Tsuji A, Inukai M, Yamakawa T, Yamatsuji T, Yoshimitsu M, Toyota K, Yamano T, Nagasaka T, Okajima M.

Drug Des Devel Ther. 2016 Nov 23;10:3827-3835. eCollection 2016.

6.

Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.

Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P, Frigeni B, Cacciavillani M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP.

J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):392-8. doi: 10.1136/jnnp-2013-305334. Epub 2013 Jun 29.

PMID:
23813745
7.

Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.

Reddy SM, Vergo MT, Paice JA, Kwon N, Helenowski IB, Benson AB, Mulcahy MF, Nimeiri HS, Harden RN.

Clin Colorectal Cancer. 2016 Mar;15(1):37-46. doi: 10.1016/j.clcc.2015.07.001. Epub 2015 Jul 26.

PMID:
26337211
8.

Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.

Kokotis P, Schmelz M, Kostouros E, Karandreas N, Dimopoulos MA.

Clin Colorectal Cancer. 2016 Sep;15(3):e133-40. doi: 10.1016/j.clcc.2016.02.009. Epub 2016 Feb 27.

PMID:
27038553
9.

Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.

Tofthagen C, McAllister RD, McMillan SC.

Clin J Oncol Nurs. 2011 Apr;15(2):182-8. doi: 10.1188/11.CJON.182-188.

PMID:
21444285
10.

[Promising effects of pregabalin in the treatment of oxaliplatin-induced sensory neuropathy in patients with colorectal carcinoma].

Nagahara H, Noda E, Maeda K, Inoue T, Hirakawa T, Hasegawa T, Shibutani M, Hirakawa K.

Gan To Kagaku Ryoho. 2013 Sep;40(9):1181-3. Japanese.

PMID:
24047775
11.

Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir.

Coriat R, Alexandre J, Nicco C, Quinquis L, Benoit E, Chéreau C, Lemaréchal H, Mir O, Borderie D, Tréluyer JM, Weill B, Coste J, Goldwasser F, Batteux F.

J Clin Invest. 2014 Jan;124(1):262-72. doi: 10.1172/JCI68730. Epub 2013 Dec 20.

12.

Oxaliplatin-induced neuropathy: a tale of two electrolytes.

Babiker HM, Green MR, Nelson MA, Elquza E.

Support Care Cancer. 2015 Jun;23(6):1483-5. doi: 10.1007/s00520-015-2702-0. Epub 2015 Mar 24. No abstract available.

PMID:
25801447
13.

A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.

Beijers AJ, Mols F, Vreugdenhil G.

Support Care Cancer. 2014 Jul;22(7):1999-2007. doi: 10.1007/s00520-014-2242-z. Epub 2014 Apr 13. Review.

PMID:
24728618
14.

Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.

Zhu Y, Yang J, Jiao S, Ji T.

World J Surg Oncol. 2013 Jan 25;11:19. doi: 10.1186/1477-7819-11-19.

15.

Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis.

Wen F, Zhou Y, Wang W, Hu QC, Liu YT, Zhang PF, Du ZD, Dai J, Li Q.

Ann Oncol. 2013 Jan;24(1):171-8. doi: 10.1093/annonc/mds211. Epub 2012 Aug 16.

PMID:
22898039
16.

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.

Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, Thomas RR, Grem JL.

BMC Cancer. 2005 Sep 16;5:116.

17.

Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.

Beijers AJ, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, Vreugdenhil G.

Acta Oncol. 2015 Apr;54(4):463-9. doi: 10.3109/0284186X.2014.980912. Epub 2014 Nov 24.

PMID:
25417732
18.

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F.

Ann Oncol. 2012 Jan;23(1):200-5. doi: 10.1093/annonc/mdr045. Epub 2011 Mar 22.

PMID:
21427067
19.

Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.

Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M.

Asian Pac J Cancer Prev. 2015;16(17):7603-6.

20.

Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.

McHugh JC, Tryfonopoulos D, Fennelly D, Crown J, Connolly S.

Eur J Cancer Care (Engl). 2012 Nov;21(6):782-9. doi: 10.1111/j.1365-2354.2012.01361.x. Epub 2012 May 17.

PMID:
22594346

Supplemental Content

Support Center